The World Health Organisation (WHO) on Monday issued global guidelines recommending GLP-1 drugs for the long-term treatment of obesity. According to the WHO, this disease affects more than 1 billion people worldwide. The decision comes at a time when demand for drugs like semaglutide and tirzepatide has surged, and countries are working on how to include these therapies in public health systems. This announcement now formalises a shift that could influence medical policy, insurance coverage, and the global effort to combat obesity.

What exactly are GLP-1 drugs?

GLP-1 (Glucagon-Like Peptide-1) drugs mimic a hormone produced in the gut that regulates appetite, digestion, and blood sugar. They help slow gastric emptying so that individuals feel full for longer, reduce hunger signals, and im

See Full Page